Breaking News Instant updates and real-time market news.

ACHC

Acadia

$45.19

1.75 (4.03%)

07:35
10/19/16
10/19
07:35
10/19/16
07:35

Acadia still has positive catalysts despite ' stumble,' says RBC Capital

RBC Capital analyst Frank Morgan says that Acadia's Q3 miss was "a stumble," driven partly by the resolution of its Priory antitrust issues. The analyst thinks that the stock could drop another 5%-10%, but he says that its Q4 results and its reinvestment of the $390M of proceeds from the Priory deal should provide positive catalysts for the shares. The analyst keeps a $59 price target and Outperform rating on the stock.

ACHC Acadia
$45.19

1.75 (4.03%)

07/15/16
JEFF
07/15/16
NO CHANGE
Target $85
JEFF
Buy
Acadia selloff yesterday a buying opportunity, says Jefferies
Jefferies analyst Brian Tanquilut believes Acadia Healthcare investors overreacted to the U.K.'s Competition & Markets Authority expressing anti-competitive concerns in 20 of the company's U.K. markets due to its Priory acquisition. Acadia management is committed to pursuing a compromise that is acceptable to the agency within the next five that should lead to final approval of the Priory deal by July 28, Tanquilut tells investors in a research note. He views yesterday's pullback in Acadia shares as a buying opportunity. The analyst keeps a Buy rating on the name with an $85 price target.
06/28/16
LEER
06/28/16
NO CHANGE
LEER
Outperform
Acadia more exposed to the U.K. but sell-off appears 'overdone,' says Leerink
Leerink analyst Ana Gupte believes Managed Care Organizations will be immune from Brexit, as they are macro defensive with minimal earnings exposure. However, the analyst notes that Acadia Healthcare is the "most exposed" to the U.K. among the Managed Care names in her coverage, but says she expects modest EBITDA downside at about 4% for fiscal year 2017. Gupte recommends Acadia as a buying opportunity amid the stock's sell-off. Leerink has an Outperform rating on the shares.
06/27/16
JEFF
06/27/16
NO CHANGE
Target $85
JEFF
Acadia pullback Friday a buying opportunity, says Jefferies
Jefferies analyst Brian Tanquilut views Friday's pullback in shares of Acadia Healthcare as overdone. The company's exposure to the Brisith pound weakness is fairly minimal, and investors can now focus on fundamentals with the Brexit vote done, Tanquilut tells investors in a research note. The analyst left recent meetings with management "even more bullish" on Acadia's fundamentals and growth outlook. He keeps a Buy rating on the shares with an $85 price target.
04/26/16
BARD
04/26/16
NO CHANGE
BARD
Outperform
Acadia, Universal Health should rally after positive Medicaid ruling, says Baird
Baird said the Medicaid ruling which eliminates the historically discriminatory IMD exclusion sets up an accelerating growth profile for both Acadia (ACHC) and Universal Health (UHS) by expanding their addressable market by 7-9%. The firm expects both company's shares to rally and reiterated Outperform ratings on both Acadia and Universal Health.

TODAY'S FREE FLY STORIES

HRTX

Heron Therapeutics

$13.75

-0.1 (-0.72%)

08:03
02/24/17
02/24
08:03
02/24/17
08:03
Hot Stocks
Heron Therapeutics reports inclusion of SUSTOL ER injection in NCCN guidelines »

Heron Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NXTD

Nxt-ID

$2.12

-0.2 (-8.62%)

08:03
02/24/17
02/24
08:03
02/24/17
08:03
Hot Stocks
Nxt-ID responds to law firm press release »

NXT-ID responded to a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRK

Merck

$65.85

0.56 (0.86%)

, GILD

Gilead

$69.37

0.54 (0.78%)

08:02
02/24/17
02/24
08:02
02/24/17
08:02
Recommendations
Merck, Gilead, AbbVie analyst commentary  »

Merck write-down suggests…

MRK

Merck

$65.85

0.56 (0.86%)

GILD

Gilead

$69.37

0.54 (0.78%)

ABBV

AbbVie

$61.94

0.58 (0.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

  • 06

    Mar

  • 06

    Mar

  • 08

    Mar

  • 09

    Mar

  • 15

    Mar

  • 17

    Mar

  • 01

    Apr

  • 10

    May

  • 27

    May

  • 14

    Jun

AES

AES Corp.

$11.75

0.15 (1.29%)

08:02
02/24/17
02/24
08:02
02/24/17
08:02
Hot Stocks
AES Corp., AIMCo to acquire sPower from Fir Tree Partners for $853M plus debt »

The AES Corporation and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 28

    Feb

VALE

Vale

$10.75

-0.49 (-4.36%)

08:02
02/24/17
02/24
08:02
02/24/17
08:02
Periodicals
Vale CEO Ferreira to step down, DJ reports »

Dow Jones has corrected…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MA

MasterCard

$110.74

1.3 (1.19%)

08:01
02/24/17
02/24
08:01
02/24/17
08:01
Hot Stocks
MasterCard to integrate Masterpass into Gulf Oil's Gulf Pay »

Mastercard announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Mar

VALE

Vale

$10.75

-0.49 (-4.36%)

08:01
02/24/17
02/24
08:01
02/24/17
08:01
Options
Vale put buyer realizes 25% same-day gains »

Notable profits for the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SATS

EchoStar

$55.24

-0.29 (-0.52%)

08:01
02/24/17
02/24
08:01
02/24/17
08:01
Earnings
EchoStar reports Q4 EPS 40c, consensus 38c »

Reports Q4 revenue $740M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FLS

Flowserve

$46.78

-1.87 (-3.84%)

08:00
02/24/17
02/24
08:00
02/24/17
08:00
Hot Stocks
Flowserve names Jay Roueche interim CEO, effective immediately »

Flowserve Corporation,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZYNE

Zynerba

$22.10

0.27 (1.24%)

07:59
02/24/17
02/24
07:59
02/24/17
07:59
Initiation
Zynerba initiated  »

Zynerba initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

NGVT

Ingevity

$54.35

-2.06 (-3.65%)

07:58
02/24/17
02/24
07:58
02/24/17
07:58
Recommendations
Ingevity analyst commentary  »

Ingevity weakness creates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USM

U.S. Cellular

$44.84

-0.37 (-0.82%)

07:58
02/24/17
02/24
07:58
02/24/17
07:58
Earnings
U.S. Cellular sees FY17 revenue $3.8B-$4B, consensus $4.05B »

Sees FY17 adjusted EBITDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

BSX

Boston Scientific

$24.48

-0.68 (-2.70%)

07:57
02/24/17
02/24
07:57
02/24/17
07:57
Recommendations
Boston Scientific analyst commentary  »

Selloff in Boston…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 17

    Mar

  • 04

    May

USM

U.S. Cellular

$44.84

-0.37 (-0.82%)

07:57
02/24/17
02/24
07:57
02/24/17
07:57
Earnings
U.S. Cellular reports Q4 EPS (7c), consensus (25c) »

Reports Q4 revenue $991M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

BMY

Bristol-Myers

$55.77

0.42 (0.76%)

07:57
02/24/17
02/24
07:57
02/24/17
07:57
Hot Stocks
Bristol-Myers' Abatacept designated as orphan treatment of IIM »

Bristol-Myers'…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

  • 17

    Mar

  • 01

    Apr

TDS

Telephone and Data

$32.72

-0.03 (-0.09%)

07:56
02/24/17
02/24
07:56
02/24/17
07:56
Earnings
Telephone and Data sees FY17 revenue $5.015B-$5.265B, consensus $5.29B »

Sees FY17 adjusted EBITDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 06

    Mar

JNJ

Johnson & Johnson

$120.90

2.18 (1.84%)

07:55
02/24/17
02/24
07:55
02/24/17
07:55
Hot Stocks
Janssen's Stelara designated as orphan treatment of pediatric ulcerative colitis »

Janssen's Stelara…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 27

    Feb

  • 09

    Mar

  • 14

    Mar

  • 27

    Mar

NVRO

Nevro

$94.25

-2.26 (-2.34%)

07:55
02/24/17
02/24
07:55
02/24/17
07:55
Recommendations
Nevro analyst commentary  »

Nevro price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RSPP

RSP Permian

$40.36

-0.55 (-1.34%)

07:55
02/24/17
02/24
07:55
02/24/17
07:55
Conference/Events
RSP Permian to hold a special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 28

    Feb

  • 20

    Mar

ETN

Eaton

$72.12

-0.38 (-0.52%)

07:55
02/24/17
02/24
07:55
02/24/17
07:55
Conference/Events
Eaton to host analyst meeting »

Analyst meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 07

    Mar

TDS

Telephone and Data

$32.72

-0.03 (-0.09%)

07:54
02/24/17
02/24
07:54
02/24/17
07:54
Earnings
Telephone and Data reports Q4 EPS (5c), consensus (5c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 06

    Mar

TDS

Telephone and Data

$32.72

-0.03 (-0.09%)

07:51
02/24/17
02/24
07:51
02/24/17
07:51
Hot Stocks
Telephone and Data raises quarterly dividend to 15.5c per share »

Payment will be made on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 06

    Mar

TERP

TerraForm Power

$11.40

-0.16 (-1.38%)

07:51
02/24/17
02/24
07:51
02/24/17
07:51
Earnings
TerraForm Power reports Q3 EPS (29c), consensus (16c) »

Reports Q3 revenue $178M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHOO

Steven Madden

07:50
02/24/17
02/24
07:50
02/24/17
07:50
Recommendations
Steven Madden analyst commentary  »

Steven Madden price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

PEG

PSEG

$44.25

-0.02 (-0.05%)

07:49
02/24/17
02/24
07:49
02/24/17
07:49
Earnings
PSEG reports Q4 adjusted EPS 54c, consensus 53c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.